Dr. Nazanin Kaatz, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 834 Sheridan St, Port Townsend, WA 98368 Phone: 360-385-2200 |
News Archive
A review of previous studies indicates that an increase in prescription drug cost sharing is associated with a decrease in drug spending and use of pharmacies; and for some chronic conditions, higher cost sharing is associated with greater use of expensive medical services, according to an article in the July 4 issue of JAMA: The Journal of the American Medical Association.
Eisai announced today that the company received a Complete Response Letter from the United States Food and Drug Administration (FDA) regarding the New Drug Application (NDA) of rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive gastroesophageal reflux disease (GERD), and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
States spend less than 2 percent of what they collect from tobacco taxes and a national tobacco settlement on smoking cessation and prevention efforts, a new report says.
A new knee-surgery device investigated by University of Missouri-Columbia researchers that will help to repair meniscus tears, which were previously defined as irreparable, has been approved by the FDA for use in humans.
The Board of Directors of CELLINK AB (publ) has, based on the authorization given by the Company's Annual General Meeting that was held on 18 December 2019, resolved on a directed share issue of 3,890,000 new shares of series B (corresponding to approximately 10 per cent of the total number of outstanding shares in the Company) at a subscription price of SEK 97 per share (the "Share Issue"), which means that the Company receives SEK 377,330,000 before transaction costs.
› Verified 4 days ago